PTK2 and pleural mesothelioma: Finally, in a phase II trial, defactinib, an orally available high-affinity FAK inhibitor, was tested versus placebo as a maintenance treatment in patients with pleural mesothelioma with at least stable disease after treatment with platinum pemetrexed [38].